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Introduction {#sec1}
============

Nearly half of the patients diagnosed with glioblastoma (GBM), the most common malignant primary brain tumor, will die within a year ([@bib27]), underlining the urgency for effective GBM therapies. Contributing to the genetic and phenotypic variability of GBM is a highly tumorigenic subpopulation of glioma stem-like cells (GSCs), which drives tumor initiation, growth, and recurrence ([@bib17]). Contingent on their inherent plasticity and survival cues that are not fully elucidated, these cells can survive and proliferate in a relatively hostile environment whereby hypoxia, acidic pH, and low nutrient levels prevail ([@bib17]). Such conditions induce cellular stress, in particular ER stress, which is known to promote pathogenesis in many diseases including cancer. ER stress, which is aberrantly high in tumors ([@bib43]) and supports various hallmarks of cancer ([@bib40]), is counteracted by the activation of the unfolded protein response (UPR), an adaptation signaling mechanism that enables tumor cells to survive under severe stress conditions ([@bib40]). The UPR engages three signaling sensors, inositol-requiring enzyme 1 (*IRE1*), protein kinase RNA-like ER kinase (*PERK*), and activating transcription factor 6 (*ATF6*) ([@bib32]), that act jointly to alleviate and resolve ER stress. UPR signaling also promotes tumor growth through various mechanisms, including the activation of lipid synthesis pathways ([@bib7]). GBM presents an upregulated lipid metabolism characterized by increased activation of sterol regulatory element-binding protein 1 (SREBP1), a master transcriptional regulator of lipid synthesis ([@bib13]), and an abundance of unsaturated fatty acids (UFAs) ([@bib34]). One of the target genes regulated by SREBP1 is stearoyl coenzyme A (CoA) desaturase 1 (*SCD1*), a key enzyme responsible for the conversion of saturated fatty acids (SFAs) to UFAs, necessary for tumor proliferation in several malignancies ([@bib16]), and the maintenance of lung and ovarian cancer stem cells ([@bib20], [@bib25]). A defining role of *SCD1* in GBM tumor initiation and growth, and the regulation mechanisms governing its activity, remain largely unexplored.

In this study, we demonstrate that persistent activation of ER stress promotes *SCD1* expression through the activation of IRE1 and SREBP1. We propose that, through its unique role of controlling intracellular levels of SFAs, SCD1 is an essential regulator of ER stress that confers a selective advantage and promotes survival of GSCs in their tumor microenvironment.

Results {#sec2}
=======

*SCD1* Is a Therapeutic Target in Highly Proliferative GSC Populations {#sec2.1}
----------------------------------------------------------------------

We have recently described a subpopulation of GSCs that escapes differentiation conditions and has enhanced stem cells properties, tumorigenic potential, and superior therapeutic resistance compared with the parental GSCs ([@bib37]). To identify targeted inhibitors with increased toxicity toward this subpopulation that we termed floating cells (FCs), we have previously performed a small-scale inhibitors screen whereby GSCs and corresponding FCs were treated with target-selective inhibitors ([@bib37]). Out of 141 compounds tested, only two inhibitors for *SCD1* and nicotinamide phosphoribosyltransferase (*NAMPT*), a recently identified therapeutic target for GBM ([@bib36]), showed increased sensitivity to the FCs compared with the parental GSCs ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Intriguingly, while *SCD1* is a prominent target gene for SREBP1, *NAMPT* has also been reported to be positively regulated by this transcription factor ([@bib30]). We primarily focused on *SCD1*, and first validated an increased sensitivity of FCs derived from two additional GSC lines to *SCD1* inhibitors (MK-8245 and CAY10566 \[CAY\]) compared with the parental GSCs ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C). Gene expression analysis showed increased expression of *SCD1* and other SREBP1 targets genes such as acyl-CoA synthetase short chain family member 2 (*ACSS2*), acetyl-CoA carboxylase α (*ACC1*), and fatty acid synthase (*FASN*) in the FC subpopulations ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1E). An upregulated mRNA and protein expression of *SCD1* ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1F), along with vulnerability to *SCD1* inhibitors, suggests an increased dependency of the FCs on *SCD1* activity. We have previously reported that FCs are characterized by aberrant activation of nuclear factor κB (NF-κB) and increased mesenchymal properties. Treatment of previously characterized proneural and mesenchymal GSCs ([@bib22]) showed a clear sensitivity to the *SCD1* inhibitor in the latter subtype ([Figure S1](#mmc1){ref-type="supplementary-material"}G). Overall, these findings suggest an increased expression and dependence on *SCD1* in highly tumorigenic GBM subpopulations.

SCD1 Is Essential for GSC Maintenance and *In Vivo* Tumor Initiation {#sec2.2}
--------------------------------------------------------------------

Palmitic Acid (PA; C16:0) is the most abundant SFA in human serum and the direct substrate of *SCD1* ([@bib2]). To functionally assess SCD1 activity *in vivo*, we tested whether PA supplementation could increase neutral lipid accumulation in GBM, detected using BODIPY, a fluorescent dye that stains neutral lipids. Indeed, tumor sections from mice receiving a daily dose of PA displayed a strong lipid staining ([Figure 1](#fig1){ref-type="fig"}A), suggesting that fractions of free PA are readily taken up by the tumor, desaturated by SCD1 before downstream processing into neutral lipids. Genetic silencing of *SCD1* with short hairpin RNA (shRNA) decreased the expression of the pluripotency markers *SOX2*, *NESTIN*, *OLIG2*, *OCT4*, and *NANOG* ([Figures 1](#fig1){ref-type="fig"}B--1D), as well as stem cell frequency ([Figure 1](#fig1){ref-type="fig"}E). Silencing of *SCD1* also decreased cell viability in five patient-derived GSCs ([Figures 1](#fig1){ref-type="fig"}F and 1G) but not in normal human astrocytes (NHAs) or immortalized neural stem cells (NSCs) maintained under serum-free conditions ([Figure 1](#fig1){ref-type="fig"}F). Supplying GSCs with oleic acid (OA; C18:1), the main product of SCD1, rescued from shSCD1-mediated cell death ([Figure 1](#fig1){ref-type="fig"}G). The role of SCD1 in tumor initiation was further evaluated by implanting GSCs expressing shSCR or shSCD1 into the striatum of nude mice. Silencing of SCD1 completely prevented tumor growth as assessed by Firefly luciferase (Fluc) bioluminescence imaging as well as overall survival up to 150 days after implantation when the experiment was terminated ([Figure 1](#fig1){ref-type="fig"}H). Ectopic expression of SCD1 using a lentivirus system (SCD1-OE; [Figure S2](#mmc1){ref-type="supplementary-material"}A) resulted in a greater than 5-fold increase in stem cell frequency in two GSCs ([Figure S2](#mmc1){ref-type="supplementary-material"}B). We repeated these experiments in one GSC specimen that was propagated long-term as neurospheres (\>50 passages) and presented a low stem cell frequency. Forced expression of SCD1 in these cells increased stem cell frequency ([Figure S2](#mmc1){ref-type="supplementary-material"}C), cell proliferation ([Figure S2](#mmc1){ref-type="supplementary-material"}D), and secondary neurosphere formation ([Figure S2](#mmc1){ref-type="supplementary-material"}E). Following intracranial implantation of these high-passage GSCs in mice, four of five mice in the SCD1-OE group developed tumors that gradually grew over time ([Figure 1](#fig1){ref-type="fig"}I), and three of five succumbed to tumor burden by day 135 post implantation when this experiment was terminated ([Figure S2](#mmc1){ref-type="supplementary-material"}F). None of the mice in the control arm developed any tumor detectable by Fluc imaging or H&E staining ([Figures 1](#fig1){ref-type="fig"}I, 1J, and [S2](#mmc1){ref-type="supplementary-material"}F). In sum, SCD1 is essential for GSC maintenance and confers a tumor growth advantage *in vivo*.Figure 1SCD1 Is Essential for GSC Maintenance and Tumor Initiation(A) Mice bearing 83-Fluc GSC tumors received daily injections over 7 days of BSA or PA (3 mg/kg of body weight). Representative brain sections were stained with BODIPY (red) and DAPI (blue). Asterisks depict the tumor injection site.(B) Immunostaining for NESTIN, SOX2, and nuclei (DAPI) in 19-GSCs expressing shSCR or shSCD1 at day 7 after shRNA transduction. Scale bar, 100 μm.(C) Immunoblot analysis of SCD1, SOX2, and NESTIN in GSCs expressing shSCR or shSCD1.(D) Relative expression of stem cell markers determined by qPCR in GSCs transduced with shSCR or shSCD1 for 7 days.(E) Stem cell frequency in 157 GSCs expressing shSCR or shSCD1 determined using the limited dilution analysis algorithm.(F) Cell viability in three GSCs, NHA, and NSC expressing shSCR or shSCD1, at day 7 after transduction. Data is expressed as percentage of shSCR.(G) GSCs (326 and 1123) expressing shSCR or shSCD1 were cultured in the presence of BSA or OA (50 μM). Cell viability was determined 7 days post transduction.(H) 83-Fluc GSCs transduced with shCtrl or shSCD1 and intracranially implanted in mice (shCtrl, n = 4; sh*SCD1*, n = 6) after 24 h. Survival analysis is shown using Kaplan-Meier curves. p = 0.0025 (two-sided log-rank test). Representative Fluc imaging of brain tumors at day 10 post implantation is also shown.(I) High-passage 157-Fluc GSCs (5 × 10^4^) expressing control (Ctrl) or SCD1 (SCD1-OE) were implanted in the brain of nude mice (n = 5/group). Longitudinal Fluc imaging shown for individual mice in each group.(J) H&E staining of brain sections of representative mice from both groups at day 135 post implantation.^∗^p \< 0.05, ^∗∗^p \< 0.001, Student's t test. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Perturbation of SCD1 Activity Depletes GSCs Regardless of Their Genetic Background {#sec2.3}
----------------------------------------------------------------------------------

We tested three pharmacological inhibitors of SCD1: PluriSIn, CAY, and the ACC1 inhibitor TOFA, which reportedly also inhibits SCD1 ([@bib23]), and identified CAY as the most cytotoxic inhibitor with an average IC~50~ \< 100 nM in different GSC specimens ([Figure S3](#mmc1){ref-type="supplementary-material"}A and data not shown). GSCs treated with CAY showed increased caspase-3 and caspase-7 activities indicative of apoptotic cell death ([Figure 2](#fig2){ref-type="fig"}A), along with increased histone H2AX phosphorylation (γ-H2AX), a marker of DNA damage ([Figure 2](#fig2){ref-type="fig"}B). NHAs were indifferent to CAY treatment under serum-free conditions ([Figure S3](#mmc1){ref-type="supplementary-material"}B). To confirm that CAY inhibits SCD1 activity, we analyzed fatty acid composition in GSCs treated with a control vehicle or CAY. We confirmed a decrease in UFAs ([Figures 2](#fig2){ref-type="fig"}C and [S3](#mmc1){ref-type="supplementary-material"}C) and observed an overall increase of SFAs, which was more pronounced around C20:0--C26:0, thereby suggesting an accumulation of SFAs after CAY treatment ([Figure 2](#fig2){ref-type="fig"}C). Next, we performed rescue experiments after treatment with this inhibitor in the presence of SFAs (16:0; 18:0), monounsaturated FAs (18:1; 16:1; 18:2), and polyunsaturated FAs (20:4 n-6; 22:6 n-3). All of the UFAs tested almost completely protected against CAY-induced cell death ([Figure 2](#fig2){ref-type="fig"}D). We treated ten patient-derived GSCs with CAY and assessed short-term (4 days) and long-term (9 days) survival. We observed two different patterns of short-term response whereby four GSCs were highly sensitive to CAY-induced cell death with an IC~50~ \< 60 nM, while six GSCs showed poor or no response ([Figure 2](#fig2){ref-type="fig"}E). However, long-term (9 days) treatment with CAY in this more resistant GSC subset (MGG8 and 157) resulted in \>80% decrease in cell viability and neurosphere formation ([Figure 2](#fig2){ref-type="fig"}F). These results establish that inhibitors of SCD1 can effectively target patient-derived GBM cells in culture regardless of subtype.Figure 2Pharmacological Targeting of SCD1 Depletes GSCs(A) Fold change in caspase-3/7 activation in 326 GSCs treated with CAY (200 nM).(B) Immunostaining for γ-H2AX in CAY-treated GSCs. Scale bar, 200 μm. Representative images of single nuclei depicting γ-H2AX foci are also shown (inset).(C) Heatmap representing the quantitative ratio of SFAs and UFAs in 83 CAY-treated GSCs relative to the untreated control. Values below or above 1 are indicative of decreased or increased fatty acids ratios, respectively.(D) Cell viability in 83-GSCs treated with CAY (100 nM) in the presence of the indicated fatty acids.(E) Cell viability at day 4 in ten GSC specimens treated with CAY at the indicated doses.(F) Cell viability and representative bright-field micrographs of secondary spheres at day 9 in 157-GSCs treated with CAY (100 nM).^∗^p \< 0.05, ^∗∗^p \< 0.001, Student's t test. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

Pharmacological Targeting of SCD1 Achieves a Strong Therapeutic Effect in GBM Mouse Models {#sec2.4}
------------------------------------------------------------------------------------------

To evaluate the therapeutic efficacy of SCD1 inhibition in GSCs xenograft mouse models, we elected to deliver CAY via the intranasal route, which allows bypassing of the blood-brain barrier ([@bib4]). Mice were implanted with mesenchymal 83-Fluc GSCs and received a daily intranasal dose of 5 mg/kg of CAY ([Figure 3](#fig3){ref-type="fig"}A). Treatment with CAY did not cause any weight loss ([Figure S3](#mmc1){ref-type="supplementary-material"}D) and resulted in an average decrease of 56% in Fluc signal at day 12 post-implantation ([Figure 3](#fig3){ref-type="fig"}B), along with decreased tumor proliferation assessed by Ki67 staining ([Figure 3](#fig3){ref-type="fig"}C). This translated into a significantly extended survival of 35 days in the treated group compared with 18 days for the control group ([Figure 3](#fig3){ref-type="fig"}D). Additionally, two of eight mice in the treated group were still alive at day 156 post implantation with no detectable tumors ([Figure S3](#mmc1){ref-type="supplementary-material"}E). Under a similar experimental setup, mice receiving a lower dose of CAY (1.5 mg/kg) also showed a significantly extended survival of 22 days in the treated group compared with 16 days for the control group (p = 0.0009; [Figure S3](#mmc1){ref-type="supplementary-material"}F). These experiments were repeated in mice bearing proneural 157-GSC brain tumors. All mice (8/8) in the control group showed growing tumors ([Figure 3](#fig3){ref-type="fig"}E) and eventually died from tumor burden ([Figure 3](#fig3){ref-type="fig"}F). Remarkably, none of the CAY-treated mice (0/8) had any detectable tumor and survived up to 158 days when the experiment was terminated ([Figures 3](#fig3){ref-type="fig"}E and 3F). We did not observe a significant change in liver weight following CAY treatment, suggesting an absence of hepatomegaly ([Figure 3](#fig3){ref-type="fig"}G). Therefore, intranasal delivery of CAY in patient-derived xenograft mouse models is a highly effective therapeutic strategy.Figure 3Therapeutic Targeting of SCD1 in Preclinical GBM Mouse Models(A) Overview of experimental setup.(B--D) Mice implanted with 83-Fluc GSCs (2 × 10^4^; n = 8/group) received a daily intranasal dose of DMSO (Control) or CAY (5 mg/kg) for 10 days. (B) Overtime monitoring of tumor growth with Fluc imaging in individual mice from Ctrl and CAY-treated groups. Hash depicts the time of death due to tumor burden. (C) Ki67 immunostaining in one Ctrl and one CAY-treated mouse. Scale bar, 100 μm. (D) Kaplan-Meier curves showing median survival in both groups (^∗^p = 0.008, two-sided log-rank test).(E--G) Mice implanted with 157-Fluc GSCs (1 × 10^5^; n = 8/group) were treated with vehicle or CAY (5 mg/kg). (E) Overtime Fluc imaging demonstrates the absence of tumor growth in all eight CAY-treated mice. (F) Survival curves in both groups (p = 0.0002; two-sided log-rank test). (G) The ratio of liver weight to the body weight in both experimental groups is shown. ns, non-significant by Student's t test.See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

SCD1 Inhibition Exacerbates ER Stress through the Accumulation of SFAs {#sec2.5}
----------------------------------------------------------------------

SFAs are known to induce ER stress ([@bib41]), hence the increased expression of the UPR transcripts *CHOP* and *sXBP1* in GSCs treated with PA ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Similarly, GSCs treated with CAY displayed a strong increase in the ER stress markers *BiP* (also known as *GRP78*), *CHOP*, *sXBP1*, and *GADD34* ([Figure 4](#fig4){ref-type="fig"}A), which was further accentuated over time ([Figure 4](#fig4){ref-type="fig"}A), in line with an increased accumulation of SFAs following SCD1 inhibition. Treatment with CAY also increased BiP (in two of the four GSCs tested) and CHOP proteins levels along with increased phosphorylation of eIF2α and γ-H2AX ([Figure 4](#fig4){ref-type="fig"}B). We hypothesized that SFA accumulation after CAY treatment primarily induces apoptotic cell death through an overwhelming ER stress response. The combination of CAY and a low dose of PA resulted in increased expression of *CHOP* and *sXBP1* transcripts ([Figure S4](#mmc1){ref-type="supplementary-material"}B), as well as protein levels of BiP, CHOP, and γ-H2AX ([Figure S4](#mmc1){ref-type="supplementary-material"}C). This combination also increased caspase-3/7 activities ([Figure 4](#fig4){ref-type="fig"}C) and cell death in GSCs but not in NHAs ([Figure 4](#fig4){ref-type="fig"}D). Similarly, silencing of SCD1 or treatment with a different SCD1 inhibitor increased PA-induced cytotoxicity ([Figures S4](#mmc1){ref-type="supplementary-material"}D and S4E). The SFA stearic acid (SA; C18:0) also increased cell death when combined with CAY ([Figure S4](#mmc1){ref-type="supplementary-material"}F). Alleviating ER stress with the chemical chaperone phenylbutyrate (PBA) significantly repressed caspase-3/7 activation ([Figure 4](#fig4){ref-type="fig"}E) and protected against SCD1 inhibition ([Figure 4](#fig4){ref-type="fig"}F). Further, azoramide, which protects against chemically induced ER stress ([@bib9]), also significantly rescued mice from CAY-induced cytotoxicity ([Figure S4](#mmc1){ref-type="supplementary-material"}G). Overall, these data demonstrate that targeting SCD1 results in chronic ER stress and renders GSCs susceptible to SFA-induced lipotoxicity.Figure 4SCD1 Inhibition Promotes ER Stress and Triggers UPR-Mediated Apoptotic Signaling(A) Relative mRNA expression of ER stress markers in GSCs treated with CAY (200 nM) for 24 and 48 h.(B) Immunoblot analysis of four GSCs treated with CAY for 48 h.(C) Fold change in caspase-3/7 activation after treatment with CAY (50 nM) in the presence or absence of PA (50 μM) or OA (50 μM).(D) Cell viability in five GSC specimens and NHA, treated with CAY (50 nM) or the combination of CAY and PA (50 μM) for 4 days.(E) Fold change in caspase-3/7 activation after treatment with CAY (50 nM) in the presence or absence of PBA (5 mM).(F) Cell viability in GSCs pretreated with CAY for 24 h followed by PBA treatment for 4 days.(G) Relative mRNA expression of *sXBP1* and *CHOP* in GSCs treated with CAY and/or OA (50 μM).(H) Immunoblot analysis of phosphorylated c-Jun in GSCs treated with CAY.(I) Cell viability of GSCs treated with CAY (50 nM) or the combination of CAY with: JNK inhibitor (SP 600125: 20 μM), IRE1 inhibitors (4μ8C: 25 μM and KIRA6: 5 μM), PERK inhibitor (GSK2656157: 10 μM), and ATF6 inhibitor (Ceapin A7: 20 μM).See also [Figures S4](#mmc1){ref-type="supplementary-material"} and [S5](#mmc1){ref-type="supplementary-material"}.

SCD1-Mediated UFA Synthesis Mitigates ER Stress {#sec2.6}
-----------------------------------------------

We postulated that transcriptional activation of SCD1 and subsequent increase in UFAs mediates a cytoprotective function in GSCs. In line with the protective effect of OA following SCD1 targeting, treatment with OA reversed PA-induced cytotoxicity ([Figure S5](#mmc1){ref-type="supplementary-material"}A) and prevented caspase-3/7 activation after treatment with CAY ([Figure 4](#fig4){ref-type="fig"}C). Importantly, OA suppressed *CHOP* and sXBP1 upregulation following CAY treatment ([Figure 4](#fig4){ref-type="fig"}G), thus suggesting that the protective role of UFAs such as OA after SCD1 inhibition is largely due to their potential role in alleviating ER stress. Ectopic expression of SCD1 reduced ER stress induced by PA or thapsigargin (Tg), as assessed by *BiP* and *sXBP1* mRNA expression ([Figure S5](#mmc1){ref-type="supplementary-material"}B), and protected against PA-induced cytotoxicity ([Figure S5](#mmc1){ref-type="supplementary-material"}C). Collectively, these results support that SCD1 acts as an essential regulator of ER stress to prevent prolonged UPR, thus favoring survival in GSCs.

Cell Death Caused by SCD1 Targeting Is Contingent on UPR Signaling {#sec2.7}
------------------------------------------------------------------

Persistent activation of UPR signals the inability of cells to adapt to ER stress, thus activating an apoptotic switch executed by CHOP or JNK ([@bib35]). Silencing of CHOP failed to protect against CAY-mediated cell death ([Figures S5](#mmc1){ref-type="supplementary-material"}D and S5E). IRE1 kinase mediates proapoptotic signaling though the activation of JNK, which directly phosphorylates and activates the transcription factor c-Jun ([@bib15]). The phosphorylation of c-Jun was transiently increased in response to CAY treatment ([Figure 4](#fig4){ref-type="fig"}H). On the other hand, treatment with JNK inhibitor SP600125 prevented caspase-3/7 activation ([Figure S5](#mmc1){ref-type="supplementary-material"}F) and reverted CAY-mediated cytotoxicity ([Figure 4](#fig4){ref-type="fig"}I). Additionally, the overexpression of a dominant-negative IRE1 ([@bib38]) (K599A) but not wild-type IRE1 produced significant rescue from cell death mediated by CAY or PA treatment ([Figure S5](#mmc1){ref-type="supplementary-material"}G). Furthermore, treatment with two IRE1 inhibitors, 4μ8C ([@bib6]) and KIRA6 ([@bib11]), prevented caspase-3/7 activation ([Figure S5](#mmc1){ref-type="supplementary-material"}F) and almost completely abrogated CAY-mediated cytotoxicity ([Figures 4](#fig4){ref-type="fig"}I, [S5](#mmc1){ref-type="supplementary-material"}H, and S5I). The ATF6 inhibitor Ceapin A7 ([@bib10]) failed to prevent cell death, while the PERK inhibitor GSK2656157 produced significant rescue from cell death in two of the three GSCs tested ([Figures 4](#fig4){ref-type="fig"}I, [S5](#mmc1){ref-type="supplementary-material"}H, and S5I). It should be noted that both PERK and IRE1 have redundant functions and are able to switch from ER stress regulators to apoptosis effectors when ER homeostasis is unattainable ([@bib14]). Overall, SCD1 inhibition induces terminal UPR signaling and triggers apoptotic cell death via IRE1 and JNK.

Adaptive ER Stress Response Promotes SCD1 Expression through SREBP1 Activation {#sec2.8}
------------------------------------------------------------------------------

Given its cytoprotective properties, we asked whether SCD1 is transcriptionally activated under ER stress in order to support GSC survival. Tg-induced ER stress resulted in a dose-dependent increase of SREBP1 transcriptional targets involved in *de novo* lipid synthesis including *SCD1*, *FASN*, *ACC1*, acyl-CoA synthetase short chain family member 2 (*ACSS2*), and ELOVL fatty acid elongase 6 (*ELOVL6*) ([Figures 5](#fig5){ref-type="fig"}A and 5B). Silencing of SREBP1 effectively decreased the expression of these genes ([Figure S6](#mmc1){ref-type="supplementary-material"}A) and, concurrently with SCD1 downregulation, resulted in a strong decrease (\>60%) in mRNA expression of stem cell markers ([Figure S6](#mmc1){ref-type="supplementary-material"}B). Furthermore, the upregulation of SREBP1 target genes by Tg, confirmed in a second GSC specimen ([Figure S6](#mmc1){ref-type="supplementary-material"}C), was reversed after SREBP1 silencing (data not shown) or concomitant treatment with 25-hydroxycholesterol (25-HC), an inhibitor of SREBP processing ([@bib1]) ([Figure S6](#mmc1){ref-type="supplementary-material"}C). ER stress-mediated increase of SCD1 protein expression was further confirmed after treatment with PA or SA ([Figure 5](#fig5){ref-type="fig"}C) or with the synthetic compound HA15, which triggers ER stress by specifically targeting BiP ([@bib3]) ([Figure S6](#mmc1){ref-type="supplementary-material"}D). Conversely, alleviating ER stress with PBA, azoramide, or tauroursodeoxycholic acid (TUCDA) downregulated SCD1 protein levels ([Figures 5](#fig5){ref-type="fig"}D and 5E). Thus, endogenous ER stress also contributes to SCD1 transcriptional regulation.Figure 5ER Stress Promotes a Lipogenic Signature through SREBP1 and IRE1 Signaling(A) *De novo* lipogenesis pathway.(B) Relative mRNA expression of SREBP1 target genes in GSCs treated with Tg (200 nM).(C--E) Protein expression of SCD1 in GSCs treated with PA and SA (C) or the ER stress inhibitors PBA (2.5, 5, and 10 mM), TUCDA (0.5 mM), and azoramide (50 μM) (D and E).(F) Immunoblot analysis showing an increased SCD1 expression in four GSCs treated with CAY (200 nM).(G) Cell viability in GSCs treated with the indicated doses of CAY in combination with T0901317 (25 μM) or SR9243 (10 μM) for 3 days.(H) Immunoblot analysis of SCD1 expression following IRE1 knockdown.(I) Relative mRNA expression of SREBP1 target genes in GSCs treated with Tg (300 nM) in the presence or absence of IRE1 inhibitor 4μ8C.^∗^p \< 0.05, ^∗∗^p \< 0.001, Student's t test. See also [Figures S6](#mmc1){ref-type="supplementary-material"} and [S7](#mmc1){ref-type="supplementary-material"}.

Intriguingly, due to the accumulation of SFAs, we observed an increased SCD1 expression following CAY treatment ([Figure 5](#fig5){ref-type="fig"}F). Blocking SCD1 transcriptional activation would prevent *de novo* synthesis of this desaturase and likely increase cytotoxicity of SCD1 inhibitors. Since the nuclear receptor liver-X-receptor (LXR) directly activates the expression of SREBP1, we used a selective LXR agonist T0901317, and an inverse agonist SR9243, to forcibly activate or repress LXR, respectively. The LXR inverse agonist effectively decreased SCD1 expression, which was increased after treatment with the LXR agonist ([Figure S6](#mmc1){ref-type="supplementary-material"}E). Concomitant treatment with SR9243 and CAY further increased ER stress markers compared with the SCD1 inhibitor alone ([Figure S6](#mmc1){ref-type="supplementary-material"}F). Unexpectedly, despite a strong downregulation of SCD1 by SR9243, the latter did not cause any significant increase in ER stress ([Figure S6](#mmc1){ref-type="supplementary-material"}F) or cytotoxicity ([Figure S6](#mmc1){ref-type="supplementary-material"}G). This is likely justified by the lack of SFA biosynthesis and accumulation after LXR inhibition. On the other hand, the combined treatment of SR9243 with low doses of CAY (\<25 nM) decreased GSC viability ([Figures 5](#fig5){ref-type="fig"}G and [S6](#mmc1){ref-type="supplementary-material"}H), while the LXR agonist T0901317 protected from CAY-mediated cell death ([Figure 5](#fig5){ref-type="fig"}G). Collectively, our data suggest that cytotoxicity caused by SCD1 inhibition is primarily due to toxic accumulation of SFAs. Therefore, targeting SCD1 and not upstream lipogenesis regulators is likely to achieve the best therapeutic outcome.

IRE1 Signaling Is Essential for Transcriptional Activation of *De Novo* Lipid Synthesis Genes {#sec2.9}
---------------------------------------------------------------------------------------------

Given that sustained IRE1 activity promotes cell survival under ER stress, we asked whether IRE1 is an upstream regulator of SREBP1 transcriptional activity. The overexpression of IRE1 that is sufficient to activate IRE1 signaling increased *XBP1* splicing ([Figure S7](#mmc1){ref-type="supplementary-material"}A) and upregulated SREBP1 target genes ([Figure S7](#mmc1){ref-type="supplementary-material"}B). On the other hand, silencing of IRE1 resulted in a decreased expression of SREBP1 targets including *SCD1* ([Figures 5](#fig5){ref-type="fig"}H and [S7](#mmc1){ref-type="supplementary-material"}C) and prevented their upregulation following Tg treatment ([Figure S7](#mmc1){ref-type="supplementary-material"}C). Finally, concurrent treatment with Tg and the IRE1 inhibitor 4μ8C prevented *XBP1* splicing ([Figure S7](#mmc1){ref-type="supplementary-material"}D) and essentially suppressed the upregulation of lipogenesis target genes ([Figure 5](#fig5){ref-type="fig"}I). Taken together, these results indicate that IRE1 controls the transcriptional activation of SREBP1 targets including SCD1.

The Expression of BiP Predicts Response to SCD1 Inhibition {#sec2.10}
----------------------------------------------------------

Elevated expression of BiP, the putative marker of ER stress, is commonly observed in various malignancies including GBM ([@bib28]). Analysis of The Cancer Genome Atlas (TCGA) database confirmed that *BiP* expression is significantly increased in GBM compared with non-tumor tissue ([Figure 6](#fig6){ref-type="fig"}A), and elevated levels of *BiP* correlated with poor survival ([Figure 6](#fig6){ref-type="fig"}B). Furthermore, concordant with an increased *SCD1* expression by ER stress, we observed a positive correlation between the transcriptional levels of *BiP* and *SCD1* in GBM patients using the TCGA datasets (Pearson\'s r = 0.2686; p \< 0.0001; [Figure S7](#mmc1){ref-type="supplementary-material"}E). We then compared SCD1 and BiP protein expression across different GSCs. Interestingly, we observed a strong correlation between high BiP expression and sensitivity to SCD1 inhibitors; all four GSCs (L0, L1, 83, and 326) that were highly responsive to CAY treatment ([Figure 2](#fig2){ref-type="fig"}E) presented the highest BiP protein expression ([Figure 6](#fig6){ref-type="fig"}C), suggesting that GSCs with elevated endogenous ER stress are more dependent on SCD1. This was confirmed in the FC population which, in addition to increased expression of SREBP1 targets ([Figure S1](#mmc1){ref-type="supplementary-material"}D), showed increased levels of ER stress markers compared with their parental neurospheres ([Figures S7](#mmc1){ref-type="supplementary-material"}F and S7G). Additionally we initially reported that GSCs with mesenchymal properties are highly sensitive to short-term cytotoxicity of SCD1 inhibitors ([Figure S1](#mmc1){ref-type="supplementary-material"}G). TCGA analysis of *BiP* and *CHOP*, across the three main GBM subtypes, shows that mesenchymal GBM expresses high levels of *BiP* and *CHOP* compared with proneural and classical subtypes ([Figure S7](#mmc1){ref-type="supplementary-material"}H). Overall, GBM tumors with increased ER stress, which is often linked to an aggressive tumor behavior and poor prognosis, are increasingly vulnerable to SCD1 inhibition.Figure 6The Expression of BiP Is Increased in GBM and Predicts Sensitivity to SCD1 Inhibition(A) TCGA analysis of *BiP* mRNA expression in normal non-tumor and GBM.(B) Survival analysis in 525 GBM patients from the TCGA dataset based on high versus low *BiP* expression levels. p = 0.0005, log-rank test.(C) Immunoblot analysis of SCD1 and BiP expression in NHA and eight GSC specimens.See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

SCD1 Inhibition Downregulates DNA-Repair Mechanisms and Enhances Temozolomide Cytotoxicity {#sec2.11}
------------------------------------------------------------------------------------------

ER stress-inducing compounds can impair DNA-repair mechanisms and therefore sensitize to the conventional GBM therapeutic temozolomide (TMZ) ([@bib44], [@bib45]), which in itself induces ER stress in GBM ([@bib28]). Treatment of GSCs with TMZ resulted in a modest increase in mRNA expression of *CHOP* and *sXBP1* (\<3-fold) ([Figure 7](#fig7){ref-type="fig"}A). The combination of CAY and TMZ displayed an overall increase in ER stress markers compared with CAY alone ([Figure 7](#fig7){ref-type="fig"}A). To assess whether this increase is caused by SFAs, we treated GSCs with TMZ and a relatively low dose of PA. Remarkably, the combination of TMZ with PA led to a prominent upregulation of all four markers ([Figure 7](#fig7){ref-type="fig"}A). Treatment with CAY in GSCs specimens consistently decreased the expression of the DNA-repair protein RAD51, which contributes to GSC resistance to radiation therapy and TMZ ([@bib33]) ([Figure 7](#fig7){ref-type="fig"}B). As such, treatment with CAY and TMZ resulted in increased levels of γ-H2AX ([Figures 7](#fig7){ref-type="fig"}B and 7C) and caspase-3/7 activation even in MGG23, a TMZ-resistant GSC with unmethylated MGMT promoter ([@bib42]) ([Figure 7](#fig7){ref-type="fig"}D). Importantly, treatment with CAY (10--100 nM) increased TMZ cytotoxicity in TMZ-responsive GSCs and sensitized to TMZ in TMZ-resistant GSCs ([Figure 7](#fig7){ref-type="fig"}E). For instance, in MGG23 this combination decreased cell viability by ∼60% ([Figure S7](#mmc1){ref-type="supplementary-material"}I) and depleted secondary sphere formation ([Figures 7](#fig7){ref-type="fig"}F and 7G). Treatment with PA (but not OA) also strongly sensitized to TMZ ([Figures S7](#mmc1){ref-type="supplementary-material"}J and S7K). Finally, CAY-mediated sensitization to TMZ, which was confirmed in one additional GSC specimen ([Figure 7](#fig7){ref-type="fig"}H), could be completely reversed by alleviating ER stress or by inhibiting PERK or IRE1 ([Figure 7](#fig7){ref-type="fig"}H). Overall, these data indicate that ER stress induced by the accumulation of SFAs impairs RAD51-mediated DNA-repair mechanisms, thus sensitizing to TMZ.Figure 7SCD1 Inhibition Compromises DNA Damage Repair and Increases Temozolomide Cytotoxicity(A) Relative mRNA expression of ER stress markers in 83-GSCs treated with CAY (200 nM), PA (200 μM), TMZ (100 μM), or their respective combination as indicated.(B) Immunoblot analysis of Rad51 and γ-H2AX in GSCs treated with CAY and TMZ.(C) Immunostaining for γ-H2AX in 83-GSCs treated with CAY (50 nM) and TMZ (100 μM). Scale bar, 200 μm. Representative images of single nuclei depicting γ-H2AX foci are also shown (inset).(D) Fold change in caspase-3/7 activation in GSCs pretreated with CAY (200 nM) followed by TMZ treatment (100 μM).(E) GSCs were pretreated with CAY for 24 h prior to TMZ treatment. Cell viability was measured after 5 days. MGG8 were treated with CAY (100 nM) and TMZ (0--10 μM). GSCs (83 and L0) were treated with CAY (10 nM) and TMZ (0--100 μM).(F and G) MGG23 were pretreated with CAY (100 nM) for 24 h followed by TMZ (100 μM) for 7 days. Secondary spheres were counted 15 days after treatment (F). Micrographs of neurospheres are shown in (G). Scale bar, 100 μm.(H) Cell viability in 326-GSCs after 7 days of treatment with CAY (10 nM), TMZ (50 μM), or their combination in the presence of OA, PBA, azoramide, PERK, or IRE1 inhibitor.See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

Aberrant activation of UPR signaling is intimately associated with several hallmarks of cancer and is reported in different tumor types including GBM ([@bib26]). This high dependence on UPR signaling creates a vulnerability that could be exploited to target these tumors. In this study, we have identified an increased activation and dependence on SCD1 activity that is necessary for GSC maintenance and proliferation. IRE1 signaling typically promotes survival under low or moderate ER stress and contributes to GBM progression ([@bib19]). However, under irremediable ER stress, IRE1 converts to a proapoptotic signaling ([@bib14]). Following a similar paradigm, we show that in GBM, IRE1 activation of SREBP1 transcriptional targets, which include SCD1, promotes survival under ER stress. While we have not addressed the mechanism by which IRE1 activates SREBP1, it was previously reported that sXBP1, a key transcription factor downstream of IRE1, can directly interact with SREBP1 promoter ([@bib24]). Disruption of SCD1 activity in GSCs prevents synthesis of UFAs required for membrane synthesis and cell proliferation and causes a toxic accumulation of SFAs, thus leading to terminal UPR signaling mediated by JNK. In line with our findings, SREBP1 and its target SCD1 were shown to be upregulated under hypoxic conditions in GBM ([@bib18]). This is possibly caused by IRE1 activation since hypoxia is known to activate the UPR, including IRE1-XBP1 signaling ([@bib31]). Additionally, IRE1 activates downstream oncogenic signaling such as NF-κB ([@bib7]), a regulator of SCD1 in ovarian cancer stem cells ([@bib20]). Therefore, it is likely that IRE1-mediated activation of SREBP1 targets is not limited to GBM. Our work also extends our previous findings whereby we have characterized a subpopulation of GBM stem cells with increased tumorigenic potential and aberrant activation of NF-κB ([@bib37]). Interestingly, we have previously determined that these cells are enriched under acidic pH or hypoxia. Here, we provide mechanistic insights detailing an activated ER stress and SREBP1 signature as well as an increased vulnerability to SCD1 inhibition in these cells. Therefore, it is likely that IRE1-XBP1-NF-κB signaling is a key driver of aggressive GBM subpopulations.

An upregulation of SREBP1-mediated lipid synthesis is both a prerequisite and a consequence of the increased proliferation of tumor cells, potentially fueled by the biochemical environment of GBM, or endogenously by oncogenic stress, genomic instability, or misfolded proteins, all of which promote ER stress and UPR signaling. ER stress is further compounded by an avid uptake of free SFAs such as PA, the most abundant SFA in human serum and in most diets. Based on our mechanistic findings, and given its cytoprotective function, we propose that SCD1 activation is a metabolic adaptation by tumor cells to mitigate cellular damage under prolonged ER stress. This, in addition to its critical role in UFA synthesis essential for tumor cell proliferation and signaling, creates a "non-oncogene addiction" to SCD1 activity in GBM.

Prominent ER stress characterized by elevated expression of BiP renders GBM cells highly susceptible to SCD1 inhibition. An increased expression of BiP is commonly observed in cancer and correlates with chemoresistance ([@bib21], [@bib29]). Since the upregulation of SCD1 is part of the cellular adaptation to ER stress, and SCD1 expression promotes self-renewal and tumor growth, increased SCD1 expression is de facto linked to therapeutic resistance. Indeed, SCD1 was found to be upregulated in TMZ-resistant GBM cell lines, and this upregulation reportedly promotes resistance to TMZ through the activation of AKT signaling ([@bib8]). ER stress can affect genomic stability and DNA-repair mechanisms ([@bib5]). SCD1 inhibition resulted in increased DNA damage. Furthermore, the UPR triggers aberrant proteasomal degradation of proteins, a process referred to as ER-associated degradation ([@bib39]). Accordingly, we propose an alternative mechanism of TMZ sensitization in GSCs with impaired SCD1 activity, primarily driven by overwhelming ER stress and the ensuing UPR-mediated degradation of RAD51.

Our study provides a proof of concept that effective pharmacological targeting of SCD1 achieves a strong therapeutic outcome, since intranasal delivery of CAY at relatively low doses significantly improved overall survival in one GSCs xenograft mouse model and completely prevented tumor growth with a 100% cure rate in a second model. This strong *in vivo* therapeutic outcome is likely attributed to a heightened ER stress and therefore increased vulnerability to SCD1 inhibition in the tumor environment. While this outcome is very promising, there are significant challenges that remain pertinent. One key question is the ideal delivery route of such inhibitors in humans in a way to maximize brain tumor penetrance and minimize systemic toxicity. We propose that delivery of therapeutics such as SCD1 inhibitors through nasal instillation warrants careful consideration and should be evaluated. This technique has several advantages, chief among which is its ability to bypass the blood-brain barrier ([@bib4]) and minimize systemic toxicity due to rapid delivery of molecules directly to the brain. For clinical evaluation of such therapy, target engagement and effectiveness of SCD1 inhibitors could be evaluated in patients through *in vivo* proton magnetic resonance spectroscopy, which can readily detect lipid peaks and predominantly those corresponding to UFAs ([@bib12]).

Our *in vivo* results strongly suggest that free UFAs cannot circumvent or protect from SCD1 inhibition. It should be noted that all experimental animals were fed *ad libitum* with a chow diet, which contains a significant amount of fatty acids, in particular OA. Furthermore, we argue that the overwhelming cytotoxicity caused by SCD1 inhibition is due to toxic accumulation of SFAs in the tumor and ensuing ER stress. Based on our results, targeting of SCD1, but not general regulators of lipogenesis (SREBP1, LXR) or other *de novo* lipogenesis enzymes upstream of SCD1, is likely to be most effective because of the resulting accumulation of SFAs.

Taken together, our findings reveal that SCD1 activity provides a survival advantage for GBM cancer stem cells, which presents a metabolic vulnerability to SCD1 inhibition. We provide preclinical evidence that effective targeting of this enzyme can achieve a robust therapeutic outcome for this incurable brain cancer.

Experimental Procedures {#sec4}
=======================

Cell-Based Assays {#sec4.1}
-----------------

CellTiter-Glo (Promega) was used to measure cell viability. CellTiter 96 Aqueous One Solution (Promega) was used to measure cell proliferation. Caspase-3/7 activity was detected using Caspase-Glo 3/7 (Promega). All reagents were used as recommended by the manufacturer. For data analysis, each data point in the treated samples was normalized to its respective vehicle or pretreatment control. Detailed methods for different experiments can be found in the [Supplemental Information](#app2){ref-type="sec"}.

Immunoblot Analysis {#sec4.2}
-------------------

Cells were lysed in RIPA buffer (Boston Bio Products) supplemented with protease and phosphatase inhibitors. Proteins were quantified using the Bradford protein determination assay (Bio-Rad), and 20--30 μg of protein were loaded and resolved on 10% NuPAGE Bis-Tris gels (Life Technologies) then transferred to nitrocellulose membranes (Bio-Rad) before incubation with the indicated antibodies. Proteins were detected using SuperSignal West Pico Chemiluminescent Substrate (Pierce).

Immunocytochemistry {#sec4.3}
-------------------

Cells grown as neurospheres were fixed with ice-cold acetone for 20 min. Cells were mounted on slides, air dried, permeabilized with 0.1% Triton X-100, and simultaneously blocked with 5% BSA for 1 h at room temperature. Cells were incubated overnight at 4°C with γ-H2AX antibody (1:400) or SOX2 and NESTIN antibodies (1:100). Fluorophore-conjugated secondary antibodies (Life Technologies, 1:100) were then added and incubated for 1 h. Cell nuclei were counterstained with DAPI (Life Technologies), mounted on a microscope slide, and analyzed by fluorescence microscopy.

Mouse Orthotopic Brain Tumor Models {#sec4.4}
-----------------------------------

All animal studies were approved by the Massachusetts General Hospital Subcommittee on Research Animal Care and complied with guidelines set forth by the NIH Guide for the Case and Use of Laboratory Animals. GSCs (at the indicated dose) expressing Firefly luciferase (Fluc) were stereotactically implanted into the left forebrain of nude mice (2.5 mm lateral and 0.5 mm anterior to bregma, at a 2.5-mm depth from the skull surface). Tumor initiation and growth were monitored by imaging Fluc bioluminescence activity using a Xenogen IVIS 200 Imaging System (PerkinElmer), after intraperitoneal (i.p.) injections of D-luciferin (150 mg/kg body weight) (Gold Biotechnology). Image intensity was quantitated using the Living Image software 4.3.1 (PerkinElmer). CAY was delivered by topical instillation in the nose; this compound was initially dissolved in DMSO (100 mM). CAY was freshly resuspended in a 20% solution of (2-hydroxypropyl)-β-cyclodextrin (Sigma) and injected dropwise intranasally (final volume 20 μL). PA was delivered by i.p. injections.

Histological Analysis {#sec4.5}
---------------------

Brains were collected following euthanasia, fixed in 4% paraformaldehyde, and cryoprotected in sucrose solution. Brain sections were prepared from fresh-frozen brain and subjected to H&E, BODIPY 493/503 (Thermo Fisher), or Ki67 staining according to standard protocols.

Statistical Analysis {#sec4.6}
--------------------

All cell culture experiments (with the exception of fatty acid analyses, which were performed in one replicate) consisted of a minimum of three independent replicates and were repeated at least three times. Statistical significance was calculated using a two-tailed Student\'s t test, and p values of 0.05 or less were considered significant. The results are presented as the mean ± SD. Experiments involving animal survival were analyzed using a log-rank (Mantel-Cox) test and plotted as Kaplan-Meier survival curves using GraphPad Prism. Group size was solely determined based on preliminary tests, and no statistical method was used to determine sample size.

Author Contributions {#sec5}
====================

Conceptualization, C.E.B.; Methodology, A.K.I and C.E.B.; Investigation, K.P., D.J.P., A.H., A.B.K., I.A., K.R., C.C.d.H., J.T., P.S.C., L.C., G.G.-I., A.K., and C.E.B.; Writing -- Original Draft, K.P., D.J.P., and C.E.B. Writing -- Review & Editing, K.P., D.J.P., and C.E.B.; Visualization: C.E.B.; Funding Acquisition, C.E.B.; Resources, C.E.B.; Supervision, C.E.B.

Supplemental Information {#app2}
========================

Document S1. Supplemental Experimental Procedures and Figures S1--S7Document S2. Article plus Supplemental Information

We are very grateful to Drs. Hiroaki Wakimoto (MGH), Ichiro Nakano (University of Alabama Birmingham) and Brent Reynolds (University of Florida) for providing primary GBM cells; Dr. Peter Walter (USCF/HHMI) for providing Ceapin A7; Dr. Bakhos Tannous for critical reading of the manuscript; and Dr. Anders Naar for helpful discussion and input. We also thank Dr. Luzia Sampaio and Mohamed El-Abtah for technical assistance. We acknowledge the MGH Vector Core supported by NIH/NINDS P30NS04776 and 1S10RR025504 Shared Instrumentation grant for the IVIS imaging system. This work was supported by the NIH, NCI grant K22CA197053 (to C.E.B.)

Supplemental Information can be found online at [https://doi.org/10.1016/j.stemcr.2019.02.012](10.1016/j.stemcr.2019.02.012){#intref0010}.

[^1]: Co-first author
